Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service ERCP & endoscopic ultrasound cases in Minnesota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (240 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 49 | 3,177 | 49% |
| 2020 | 45 | 2,887 | 52% |
| 2021 | 46 |
Biliary stenting, stone extraction, EUS with FNA; the advanced-endoscopy call point. Professional codes (what the surgeon bills): CPT 43264, 43274, 43260, 43259, 43242, 43266.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 48% of the cases CMS names in Minnesota; 21 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 399 | 47,636−3.7%/yr | −3.7%/yr | 109.91.0× | 35% | 59,400 in 2030+3.8%/yr |
| Bronchoscopy & lung nodule |
ERCP & endoscopic ultrasound in every state, and its device makers · Every procedure market in Minnesota · Every state · Compare with Illinois
| 2024 |
| 2,446 |
| 64% |
| 2025 est. | ≈ 2,510 | – |
| 2026 est. | ≈ 2,820 | – |
| 2,839 |
| 56% |
| 2022 | 41 | 2,564 | 59% |
| 2023 | 40 | 2,624 | 62% |
| 2024 | 37 | 2,446 | 64% |
| 2025 from claims | – | 2,507 2,300–2,652 | 65% |
| 2026 forecast | – | 2,815 2,477–3,248 | 61% |
| 2027 forecast | – | 2,886 2,468–3,440 | 61% |
| 2028 forecast | – | 2,959 2,469–3,624 | 61% |
| 2029 forecast | – | 3,034 2,478–3,805 | 60% |
| 2030 forecast | – | 3,111 2,492–3,987 | 60% |
In 2025, 42% inpatient hospital, 55% hospital outpatient, 3% surgery center.
| −2.6%/yr |
| 7.1 |
| 2% |
| 4,480 in 2030+0.8%/yr |
| Ohio | 60 | 3,607−1.1%/yr | −1.1%/yr | 3.3 | 1% | 4,620 in 2030+4.2%/yr |
| Michigan | 53 | 3,574+1.2%/yr | +1.2%/yr | 4.3 | 1% | 4,510 in 2030+4%/yr |
| Indiana | 42 | 2,562−1%/yr | −1%/yr | 3.7 | 3% | 3,260 in 2030+4.1%/yr |
| Wisconsin | 40 | 1,723−4.1%/yr | −4.1%/yr | 3.1 | 0% | 1,930 in 2030+1.9%/yr |
| Nebraska | 11 | 985−1.3%/yr | −1.3%/yr | 3.8 | 3% | 1,130 in 2030+2.4%/yr |
| Kansas | 10 | 846−4%/yr | −4%/yr | 2.1 | 2% | 840 in 2030−0.2%/yr |
| Iowa | 11 | 822−0.4%/yr | −0.4%/yr | 1.9 | 1% | 920 in 2030+2%/yr |
| North Dakota | 7 | 463+12%/yr | +12%/yr | 4.7 | 0% | 800 in 2030+9.4%/yr |
| South Dakota | 5 | 279−1.6%/yr | −1.6%/yr | 2.2 | 0% | 390 in 2030+5.9%/yr |
| 28 |
| 1,774+6.4%/yr |
| +6.4%/yr |
| 4.01.1× |
| 0% |
| 3,640 in 2030+13%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Cook leads with 33% of company spending on these surgeons in 2025, +30 pts on 2024.
In 2025, 16 companies reported engagement with Minnesota’s surgeons worth $57K in consulting, speaking, meals and travel tied to these products, about $1,537 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.